This is the authors' abstract. We don't add key points for this paper.
Novel rhodesain inhibitors were developed by combining an enantiomerically pure 3-bromoisoxazoline warhead with a 1,4-benzodiazepine scaffold as specific recognition moiety. All compounds were proven to inhibit rhodesain with Ki values in the low-micromolar range. Their activity towards rhodesain was found to be coupled to an in vitro antitrypanosomal activity, with IC50 values ranging from the mid-micromolar to a low-micromolar value for the most active rhodesain inhibitor (R,S,S)-3. All compounds showed a good selectivity against the target enzyme since all of them were proven to be poor inhibitors of human cathepsin L.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ettari et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: